Literature DB >> 27368930

Targeted stimulation of retinoic acid receptor-γ mitigates the formation of heterotopic ossification in an established blast-related traumatic injury model.

Gabriel J Pavey1, Ammar T Qureshi2, Allison M Tomasino2, Cary L Honnold3, Danett K Bishop4, Shailesh Agarwal5, Shawn Loder5, Benjamin Levi5, Maurizio Pacifici6, Masahiro Iwamoto6, Benjamin K Potter1, Thomas A Davis7, Jonathan A Forsberg1.   

Abstract

Heterotopic ossification (HO) involves formation of endochondral bone at non-skeletal sites, is prevalent in severely wounded service members, and causes significant complications and delayed rehabilitation. As common prophylactic treatments such as anti-inflammatory drugs and irradiation cannot be used after multi-system combat trauma, there is an urgent need for new remedies. Previously, we showed that the retinoic acid receptor γ agonist Palovarotene inhibited subcutaneous and intramuscular HO in mice, but those models do not mimic complex combat injury. Thus, we tested Palovarotene in our validated rat trauma-induced HO model that involves blast-related limb injury, femoral fracture, quadriceps crush injury, amputation and infection with methicillin-resistant Staphylococcus aureus from combat wound infections. Palovarotene was given orally for 14days at 1mg/kg/day starting on post-operative day (POD) 1 or POD-5, and HO amount, wound dehiscence and related processes were monitored for up to 84days post injury. Compared to vehicle-control animals, Palovarotene significantly decreased HO by 50 to 60% regardless of when the treatment started and if infection was present. Histological analyses showed that Palovarotene reduced ectopic chondrogenesis, osteogenesis and angiogenesis forming at the injury site over time, while fibrotic tissue was often present in place of ectopic bone. Custom gene array data verified that while expression of key chondrogenic and osteogenic genes was decreased within soft tissues of residual limb in Palovarotene-treated rats, expression of cartilage catabolic genes was increased, including matrix metalloproteinase-9. Importantly, Palovarotene seemed to exert moderate inhibitory effects on wound healing, raising potential safety concerns related to dosing and timing. Our data show for the first time that Palovarotene significantly inhibits HO triggered by blast injury and associated complications, strongly indicating that it may prevent HO in patients at high risk such as those sustaining combat injuries and other forms of blast trauma. Published by Elsevier Inc.

Entities:  

Keywords:  Animal model; Bioburden; Blast overpressure exposure; Endochondral ossification; Heterotopic ossification; Prophylaxis; Retinoic acid receptor-γ agonist; Traumatic extremity injury

Mesh:

Substances:

Year:  2016        PMID: 27368930      PMCID: PMC5546218          DOI: 10.1016/j.bone.2016.06.014

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  35 in total

1.  What Risk Factors Predict Recurrence of Heterotopic Ossification After Excision in Combat-related Amputations?

Authors:  Gabriel J Pavey; Elizabeth M Polfer; Kyle E Nappo; Scott M Tintle; Jonathan A Forsberg; Benjamin K Potter
Journal:  Clin Orthop Relat Res       Date:  2015-09       Impact factor: 4.176

2.  Development of an ALK2-biased BMP type I receptor kinase inhibitor.

Authors:  Agustin H Mohedas; Xuechao Xing; Kelli A Armstrong; Alex N Bullock; Gregory D Cuny; Paul B Yu
Journal:  ACS Chem Biol       Date:  2013-04-30       Impact factor: 5.100

3.  Bioburden Increases Heterotopic Ossification Formation in an Established Rat Model.

Authors:  Gabriel J Pavey; Ammar T Qureshi; Donald N Hope; Rebecca L Pavlicek; Benjamin K Potter; Jonathan A Forsberg; Thomas A Davis
Journal:  Clin Orthop Relat Res       Date:  2015-09       Impact factor: 4.176

4.  The development of a rat model to investigate the formation of blast-related post-traumatic heterotopic ossification.

Authors:  E M Polfer; D N Hope; E A Elster; A T Qureshi; T A Davis; D Golden; B K Potter; J A Forsberg
Journal:  Bone Joint J       Date:  2015-04       Impact factor: 5.082

5.  Early Characterization of Blast-related Heterotopic Ossification in a Rat Model.

Authors:  Ammar T Qureshi; Erica K Crump; Gabriel J Pavey; Donald N Hope; Jonathan A Forsberg; Thomas A Davis
Journal:  Clin Orthop Relat Res       Date:  2015-09       Impact factor: 4.176

6.  Acute and impaired wound healing: pathophysiology and current methods for drug delivery, part 1: normal and chronic wounds: biology, causes, and approaches to care.

Authors:  Tatiana N Demidova-Rice; Michael R Hamblin; Ira M Herman
Journal:  Adv Skin Wound Care       Date:  2012-07       Impact factor: 2.347

7.  Risk factors for the development of heterotopic ossification in seriously burned adults: A National Institute on Disability, Independent Living and Rehabilitation Research burn model system database analysis.

Authors:  Benjamin Levi; Prakash Jayakumar; Avi Giladi; Jesse B Jupiter; David C Ring; Karen Kowalske; Nicole S Gibran; David Herndon; Jeffrey C Schneider; Colleen M Ryan
Journal:  J Trauma Acute Care Surg       Date:  2015-11       Impact factor: 3.313

Review 8.  Heterotopic ossification following traumatic brain injury and spinal cord injury.

Authors:  Cara A Cipriano; Stephan G Pill; Mary Ann Keenan
Journal:  J Am Acad Orthop Surg       Date:  2009-11       Impact factor: 3.020

9.  Retinoic acid receptors are required for skeletal growth, matrix homeostasis and growth plate function in postnatal mouse.

Authors:  Julie A Williams; Naoki Kondo; Takahiro Okabe; Nobuo Takeshita; Diane M Pilchak; Eiki Koyama; Takanaga Ochiai; Deborah Jensen; Mon-Li Chu; Maureen A Kane; Joseph L Napoli; Motomi Enomoto-Iwamoto; Norbert Ghyselinck; Pierre Chambon; Maurizio Pacifici; Masahiro Iwamoto
Journal:  Dev Biol       Date:  2009-02-03       Impact factor: 3.582

10.  Heterotopic ossification in high-energy wartime extremity injuries: prevalence and risk factors.

Authors:  Jonathan Agner Forsberg; Joseph M Pepek; Scott Wagner; Kevin Wilson; James Flint; Romney C Andersen; Doug Tadaki; Frederick A Gage; Alexander Stojadinovic; Eric A Elster
Journal:  J Bone Joint Surg Am       Date:  2009-05       Impact factor: 5.284

View more
  25 in total

1.  Small molecule inhibition of non-canonical (TAK1-mediated) BMP signaling results in reduced chondrogenic ossification and heterotopic ossification in a rat model of blast-associated combat-related lower limb trauma.

Authors:  Amy L Strong; Philip J Spreadborough; Chase A Pagani; Ryan M Haskins; Devaveena Dey; Patrick D Grimm; Keiko Kaneko; Simone Marini; Amanda K Huber; Charles Hwang; Kenneth Westover; Yuji Mishina; Matthew J Bradley; Benjamin Levi; Thomas A Davis
Journal:  Bone       Date:  2020-07-02       Impact factor: 4.398

2.  Activin-A enhances mTOR signaling to promote aberrant chondrogenesis in fibrodysplasia ossificans progressiva.

Authors:  Kyosuke Hino; Kazuhiko Horigome; Megumi Nishio; Shingo Komura; Sanae Nagata; Chengzhu Zhao; Yonghui Jin; Koichi Kawakami; Yasuhiro Yamada; Akira Ohta; Junya Toguchida; Makoto Ikeya
Journal:  J Clin Invest       Date:  2017-07-31       Impact factor: 14.808

3.  Palovarotene Inhibits Osteochondroma Formation in a Mouse Model of Multiple Hereditary Exostoses.

Authors:  Toshihiro Inubushi; Isabelle Lemire; Fumitoshi Irie; Yu Yamaguchi
Journal:  J Bone Miner Res       Date:  2017-11-30       Impact factor: 6.741

Review 4.  Retinoid roles and action in skeletal development and growth provide the rationale for an ongoing heterotopic ossification prevention trial.

Authors:  Maurizio Pacifici
Journal:  Bone       Date:  2017-08-19       Impact factor: 4.398

Review 5.  [Research progress of traumatic heterotopic ossification].

Authors:  Guorui Cao; Fuxing Pei
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2022-03-15

Review 6.  Palovarotene: First Approval.

Authors:  Sheridan M Hoy
Journal:  Drugs       Date:  2022-04       Impact factor: 9.546

Review 7.  Pathophysiology and Emerging Molecular Therapeutic Targets in Heterotopic Ossification.

Authors:  Favour Felix-Ilemhenbhio; George A E Pickering; Endre Kiss-Toth; Jeremy Mark Wilkinson
Journal:  Int J Mol Sci       Date:  2022-06-23       Impact factor: 6.208

Review 8.  Osteochondromas: An Updated Review of Epidemiology, Pathogenesis, Clinical Presentation, Radiological Features and Treatment Options.

Authors:  Kostas Tepelenis; Georgios Papathanakos; Aikaterini Kitsouli; Theodoros Troupis; Alexandra Barbouti; Konstantinos Vlachos; Panagiotis Kanavaros; Panagiotis Kitsoulis
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

9.  Inhibition of Mammalian Target of Rapamycin Signaling with Rapamycin Prevents Trauma-Induced Heterotopic Ossification.

Authors:  Ammar T Qureshi; Devaveena Dey; Erin M Sanders; Jonathan G Seavey; Allison M Tomasino; Kaitlyn Moss; Benjamin Wheatley; David Cholok; Shawn Loder; John Li; Benjamin Levi; Thomas A Davis
Journal:  Am J Pathol       Date:  2017-10-10       Impact factor: 4.307

10.  Palovarotene Can Attenuate Heterotopic Ossification Induced by Tendon Stem Cells by Downregulating the Synergistic Effects of Smad and NF-κB Signaling Pathway following Stimulation of the Inflammatory Microenvironment.

Authors:  Junchao Huang; Jialiang Lin; Congbin Li; Bo Tang; Haijun Xiao
Journal:  Stem Cells Int       Date:  2022-04-28       Impact factor: 5.131

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.